Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thromboembolism 1Sarcoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Radiotherapy 11Brachytherapy 8fludarabine 5Radiation 5Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5Cyclophosphamide 5aldesleukin 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4Cisplatin 4fludarabine phosphate 3durvalumab 3Vaccines, Synthetic 3Radiosurgery 3Papillomavirus Vaccines 3Paclitaxel 3Methods 3Early Intervention, Educational 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tremelimumab 2entinostat 2aflibercept 2Vaccines 2Trastuzumab 2Topotecan 2Therapeutics 2Surgical Procedures, Operative 2Psychiatric Rehabilitation 2Platinum 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaginal Neoplasms × Fondaparinux × Gynecologic × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡